ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) - NCT05601752

To evaluate the anti-tumor activity of genetically modified autologous T-cells (ADP-A2M4CD8) as monotherapy and in combination with nivolumab in HLA-A*02 positive subjects with MAGE-A4 positive recurrent ovarian cancer, To evaluate safety and tolerability of ADP-A2M4CD8 as monotherapy or in combination with nivolumab, To evaluate safety of ADP-A2M4CD8 as monotherapy or in combination with nivolumab., (and 8 more...)